



Inflammatory and neurological diseases



Keywords

- Agonist
- Antagonist
- Sigma-1
- Inflammatory
- and neurological
- pathologies



Intellectual Property

WO 2015/193255



Development Status

Preclinical phase: in vivo proof of concept (mouse model)



Partnership


We are looking for a pharma or a biotech, in capacity to continue the development and bring the product to market

Technology

The Sigma-1 receptors ($\sigma 1R$) correspond to a single class of transmembrane receptors located into endoplasmic reticulum.

Expressed in the central nervous system and more particularly in neurons and oligodendrocytes, these receptors are known to be involved in the regulation of many neurotransmitters and diseases such as neurodegenerative diseases, cancer, inflammatory diseases, pain and neurological diseases.

A new family of molecules with a new structure demonstrated in vitro efficacy, selectivity and low cytotoxicity. In vivo results confirm the therapeutical potential of this new family



Benefits

- New family of ligands for Sigma-1 receptors with a good affinity and selectivity.
- The synergistic effect of Sigma-1 receptors (neuro-protection, degeneration, inflammation) is leading to a putative therapeutic impact in neurodegenerative and inflammatory diseases.

Applications

The potential applications are numerous, particularly in the treatment of pathologies such as:

- Multiple sclerosis,
- Alzheimer's disease,
- Epilepsy,
- Schizophrenia,
- Inflammatory diseases,
- Pain ...

contact

François-Xavier DENIMAL

Business Developer

+33 6 13 84 36 28

francois-xavier.denimal@sattnord.fr

find other technologies on

www.sattnord.fr



SATT Nord

25, avenue Charles St Venant – 59800 LILLE – France

+33 3 28 36 04 68 – tech@sattnord.fr